{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:39:11Z","timestamp":1792643951648,"version":"4.5.0"},"reference-count":23,"publisher":"BMJ","issue":"2","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2017,2,1]]},"published-print":{"date-parts":[[2017,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To clarify the social disadvantages associated with myasthenia gravis (MG) and examine associations with its disease and treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Cross-sectional study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting and participants<\/jats:title>\n                    <jats:p>We evaluated 917 consecutive cases of established MG seen at 13 neurological centres in Japan over a short duration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Outcome measures<\/jats:title>\n                    <jats:p>All patients completed a questionnaire on social disadvantages resulting from MG and its treatment and a 15-item MG-specific quality of life scale at study entry. Clinical severity at the worst condition was graded according to the MG Foundation of America classification, and that at the current condition was determined according to the quantitative MG score and MG composite. Maximum dose and duration of dose \u226520\u2005mg\/day of oral prednisolone during the disease course were obtained from the patients' medical records. Achievement of the treatment target (minimal manifestation status with prednisolone at \u22645\u2005mg\/day) was determined at 1, 2 and 4\u2005years after starting treatment and at study entry.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We found that 27.2% of the patients had experienced unemployment, 4.1% had been unwillingly transferred and 35.9% had experienced a decrease in income, 47.1% of whom reported that the decrease was \u226550% of their previous total income. In addition, 49.0% of the patients reported feeling reduced social positivity. Factors promoting social disadvantages were severity of illness, dose and duration of prednisolone, long-term treatment, and a depressive state and change in appearance after treatment with oral steroids. Early achievement of the treatment target was a major inhibiting factor.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Patients with MG often experience unemployment, unwilling job transfers and a decrease in income. In addition, many patients report feeling reduced social positivity. To inhibit the social disadvantages associated with MG and its treatment, greater focus needs to be placed on helping patients with MG resume a normal lifestyle as soon as possible by achieving the treatment target.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2016-013278","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T20:20:10Z","timestamp":1487967610000},"page":"e013278","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":69,"title":["Social disadvantages associated with myasthenia gravis and its treatment: a multicentre cross-sectional study"],"prefix":"10.1136","volume":"7","author":[{"given":"Yuriko","family":"Nagane","sequence":"first","affiliation":[{"name":"Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Murai","sequence":"additional","affiliation":[{"name":"Department of Neurological Therapeutics, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomihiro","family":"Imai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiko","family":"Tsuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sapporo Medical University Hospital, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoya","family":"Minami","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hokkaido Medical Center, Sapporo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Sendai Medical Center, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Kanai","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chiba University School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiyuki","family":"Uzawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Chiba University School of Medicine, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Kawaguchi","sequence":"additional","affiliation":[{"name":"Chiba Neurology Clinic, Chiba, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Masuda","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tokyo Medical University, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Konno","sequence":"additional","affiliation":[{"name":"Department of Neurology, Toho University Oh-hashi Medical Center, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Kinki University School of Medicine, Osaka, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Aoki","sequence":"additional","affiliation":[{"name":"Department of Neurology, Tohoku University Graduate School of Medicine, Sendai, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimiaki","family":"Utsugisawa","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hanamaki General Hospital, Hanamaki, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,2,23]]},"reference":[{"key":"2025121410222004000_7.2.e013278.1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.9.3.351"},{"key":"2025121410222004000_7.2.e013278.2","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20950"},{"key":"2025121410222004000_7.2.e013278.3","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/mus.23398","article-title":"The MG-QOL15 Japanese version: validation and associations with clinical factors","volume":"46","author":"Masuda","year":"2012","journal-title":"Muscle Nerve"},{"key":"2025121410222004000_7.2.e013278.4","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/mus.24213","article-title":"Health-related quality-of-life and treatment targets in myasthenia gravis","volume":"50","author":"Utsugisawa","year":"2014","journal-title":"Muscle Nerve"},{"key":"2025121410222004000_7.2.e013278.5","doi-asserted-by":"publisher","DOI":"10.1002\/ana.410150316"},{"key":"2025121410222004000_7.2.e013278.6","doi-asserted-by":"publisher","DOI":"10.3109\/08916930903518107"},{"key":"2025121410222004000_7.2.e013278.7","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s100720100066","article-title":"Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements","volume":"22","author":"Padua","year":"2001","journal-title":"Neurol Sci"},{"key":"2025121410222004000_7.2.e013278.8","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/mus.1034","article-title":"Quality of life and well-being of patients with myasthenia gravis","volume":"24","author":"Paul","year":"2001","journal-title":"Muscle Nerve"},{"key":"2025121410222004000_7.2.e013278.9","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1186\/1477-7525-8-129","article-title":"Quality of life and life circumstances in German myasthenia gravis patients","volume":"8","author":"Twork","year":"2010","journal-title":"Health Qual Life Outcomes"},{"key":"2025121410222004000_7.2.e013278.10","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-010-0285-6"},{"key":"2025121410222004000_7.2.e013278.11","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1007\/s10072-012-1170-2","article-title":"Assessment of health-related quality of life in patients with myasthenia gravis in Belgrade (Serbia)","volume":"33","author":"Basta","year":"2012","journal-title":"Neurol Sci"},{"key":"2025121410222004000_7.2.e013278.12","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s12955-015-0298-1","article-title":"An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts","volume":"13","author":"Boldingh","year":"2015","journal-title":"Health Qual Life Outcomes"},{"key":"2025121410222004000_7.2.e013278.13","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/j.jocn.2015.01.022","article-title":"Clinical features and impact of myasthenia gravis disease in Australian patients","volume":"22","author":"Blum","year":"2015","journal-title":"J Clin Neurosci"},{"key":"2025121410222004000_7.2.e013278.14","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21053"},{"key":"2025121410222004000_7.2.e013278.15","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/mus.21609","article-title":"Construct and concurrent validation of the MG-QOL15 in the practice setting","volume":"41","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"key":"2025121410222004000_7.2.e013278.16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2011-000313"},{"key":"2025121410222004000_7.2.e013278.17","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.55.1.16"},{"key":"2025121410222004000_7.2.e013278.18","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21185"},{"key":"2025121410222004000_7.2.e013278.19","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.0b013e3181dc1b1e","article-title":"The MG composite: A valid and reliable outcome measure for myasthenia gravis","volume":"74","author":"Burns","year":"2010","journal-title":"Neurology"},{"key":"2025121410222004000_7.2.e013278.20","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1002\/mus.21713","article-title":"History of outcome measures for myasthenia gravis","volume":"42","author":"Burns","year":"2010","journal-title":"Muscle Nerve"},{"key":"2025121410222004000_7.2.e013278.21","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10926-013-9490-5","article-title":"Striking a balance: work-health-personal life conflict in women and men with arthritis and its association with work outcomes","volume":"24","author":"Gignac","year":"2014","journal-title":"J Occup Rehabil"},{"key":"2025121410222004000_7.2.e013278.22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s12883-015-0375-4","article-title":"The MS@Work study: a 3-year prospective observational study on factors involved with work participation in patients with relapsing-remitting multiple sclerosis","volume":"15","author":"van der Hiele","year":"2015","journal-title":"BMC Neurol"},{"key":"2025121410222004000_7.2.e013278.23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000322497","article-title":"Early aggressive treatment strategy against myasthenia gravis","volume":"65","author":"Nagane","year":"2011","journal-title":"Eur Neurol"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2016-013278","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,14]],"date-time":"2025-12-14T18:22:29Z","timestamp":1765736549000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2016-013278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2]]},"references-count":23,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2017,2,23]]},"published-print":{"date-parts":[[2017,2]]}},"alternative-id":["10.1136\/bmjopen-2016-013278"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2016-013278","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2]]}}}